Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vir Biotechnology stock | $61.83

Own Vir Biotechnology stock in just a few minutes.

Vir Biotechnology, Inc is a biotechnology business based in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Vir Biotechnology employs 327 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Vir Biotechnology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VIR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vir Biotechnology share price

Use our graph to track the performance of VIR stocks over time.

Vir Biotechnology shares at a glance

Information last updated 2021-05-11.
Latest market close$61.83
52-week range$25.31 - $83.50
50-day moving average $47.58
200-day moving average $44.09
Wall St. target price$88.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.76

Buy Vir Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vir Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vir Biotechnology price performance over time

Historical closes compared with the close of $61.83 from 2021-03-11

1 week (2021-05-07) 43.89%
1 month (2021-04-15) 37.28%
3 months (2021-02-13) N/A
6 months (2020-11-13) 129.17%
1 year (2020-05-15) 103.72%
2 years (2019-05-13) N/A
3 years (2018-05-13) N/A
5 years (2016-05-13) N/A

Vir Biotechnology financials

Revenue TTM $76.4 million
Gross profit TTM $-196,511,000
Return on assets TTM -23.37%
Return on equity TTM -52.36%
Profit margin 0%
Book value N/A
Market capitalisation $5 billion

TTM: trailing 12 months

Shorting Vir Biotechnology shares

There are currently 8.2 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 4.1% up from 7.9 million last month.

There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.

Vir Biotechnology's "short interest ratio" (SIR)

Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 815153.66336634). Vir Biotechnology's SIR currently stands at 10.1. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 10100 shares are currently held short.

However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 60 shares are currently held short) or 0.1198% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 120 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Vir Biotechnology.

Find out more about how you can short Vir Biotechnology stock.

Vir Biotechnology share dividends

We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.

Vir Biotechnology overview

Vir Biotechnology, Inc. , a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; a collaboration, license, and option agreement with Visterra, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site